Allhat study doxazosin
Allhat study doxazosin. Oct 1, 2003 · Some 60% of treated hypertensive patients reached a blood pressure goal of < 140/90 mmHg, compared to current estimates of 34%. Understanding this heterogeneity, however, is a necessary step toward personalizing antihypertensive therapy. Nov 18, 2009 · ALLHAT was a randomized, double-blind, active-controlled clinical trial comparing the effects of amlodipine, lisinopril, or doxazosin versus chlorthalidone in patients with hypertension. , (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support provided by Pfizer,Inc. org). Nov 1, 2003 · As shown in the ALLHAT study [117], the present diuretics specially the thiazides were unsurpassed in long-term drug adherence, controlling elevated blood pressure and were superior to other These data from ALLHAT would have allowed doxazosin to have been directly compared, for the first time, to the gold standard for hypertensive therapy from an evidence-based medicine perspective Apr 6, 2005 · The baseline characteristics of the ALLHAT study population by race and treatment group are shown in Table 1. [8,10] ALLHAT recruited adults age 55 years and older with hypertension and at least 1 risk factor for CHD events (see CONSORT Diagram, Figure 1). Dr Han is The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Study, the largest double-blind, randomized trial in hypertensive patients, confirmed and strengthened the clinical relevance of thiazide diuretics in the treatment of hypertension but did not prove the superior … Nov 14, 2002 · The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized, double-blind, active-controlled trial designed to compare the rate of coronary heart disease events in high-risk hypertensive participants initially randomized to a diuretic (chlorthalidone) versus each of three alternative antihypertensive drugs: alpha-adrenergic blocker (doxazosin), ACE Mar 11, 2000 · Last month the Data Safety Monitoring Board for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) decided to discontinue the doxazosin-treatment arm of the study. The reason was “that a significantly higher percentage of patients on doxazosin developed congestive heart failure (a secondary end-point) and on the view Apr 16, 2019 · ALLHAT participants with available serial ECG s and BP measurements were included (n=29 892; mean age 67±4 years; 32% black; 56% men): 11 008 were randomized to chlorthalidone, 5967 to doxazosin, 6593 to amlodipine, and 6324 to lisinopril. JAMA 2000; 283:1967-1975. 42,418 patients were randomised, but the doxazosin arm of 9,062 patients was discontinued early at 3. Apr 19, 2000 · Objective: To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril. Jul 8, 2009 · The available data from the ALLHAT study do not suggest use of these drugs as first‐line antihypertensives Citation [5]. Jun 1, 2000 · First, since ALLHAT was not a placebo controlled trial, but rather an active controlled one, the study does not allow an assessment of whether doxazosin is better than placebo. Poulter and Williams offer an appraisal of the ALLHAT study 1 and raise many questions that, in their view, must be addressed before the results of ALLHAT become the basis for “policy decisions. The doxazosin arm was terminated early because of an excess of congestive heart failure. As published previously, ALLHAT was a randomized, double-blind, controlled trial that compared first-step antihypertensive therapies to prevent major CVD outcomes. Sep 1, 2002 · In 1997 to 1998 we conducted a relatively large local study (not to compare to the size of ALLHAT of course) in which diabetic hypertensive patients treated with angiotensin converting enzyme (ACE) inhibitor were changed to doxazosin. The ALLHAT blood pressure trial compared the effects of three blood pressure-lowering drugs—a calcium channel blocker (amlodipine), an angiotensin converting enzyme (ACE) inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)—with the effects of a diuretic (chlorthalidone), which was the control treatment in the trial. Apr 4, 2019 · The ALLHAT study was supported by the National Heart, Lung, and Blood Institute (NO1‐HC‐35130). 32) higher than the risk in patients who were treated with chlorthalidone (1). Compared with nonblacks, black participants were more Feb 1, 2021 · The ALLHAT study was supported by the National Heart, Lung, and Blood Institute grant NO1-HC-35130. On the basis of the other trial or epidemiologic data, the authors suggest that although N. [Article in German] Sep 28, 2022 · Results from the ALLHAT study (2003) showed an increased risk of doxazosin compared to chlorthalidone for combined cardiovascular events (i. It is not widely recognised that 90% of The ALLHAT study was supported by the National Heart, Lung, and Blood Institute (NO1-HC-35130). The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, also known as ALLHAT, was a randomized, double-blind, active-controlled study comparing at the same time, four different classes of antihypertensive drugs with the rate of coronary heart disease (CHD) events in ‘high-risk’ people with hypertension. Nwachuku is an employee of AstraZeneca LP, Wilmington, DE. May 31, 2007 · These data from the ALLHAT trial would have allowed doxazosin to have been directly compared, for the first time, to the gold standard for hypertensive therapy from an evidence‐based medicine perspective 19 —that is, the thiazide‐type diuretic. The ALLHAT study, the largest clinical study in hypertension ever done in the United States, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) compared four antihypertensive agents in patients 55 years and older: chlorthalidone, doxazosin, amlodipine, and lisinopril. The decision was based on the finding that a significantly higher percentage of patients on doxazosin developed congestive heart failure (which was a secondary endpoint) and on the view that Jun 1, 2000 · The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a large, randomized double-blind study comparing four antihypertensive agents (chlorthalidone, doxazosin, amlodipine, and lisinopril) in hypertensive patients older than 55 years. 5 One critical issue was the higher systolic BP among those who had been randomized to doxazosin compared with those randomized to chlorthalidone. B. ALLHAT investigators received contributions of study medications from Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol‐Myers Squibb (pravastatin), and financial support from Pfizer. From the ASCOT study, we know that doxazosin is a safe and effective drug as a third add‐on drug in the treatment of hypertension Citation [3]. Following independent data reviews on January 6 and January 21, 2000, Dec 4, 2023 · The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a multicenter, randomized, double-blind, active-controlled clinical trial comparing initial antihypertensive treatment with a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), or an α-blocker (doxazosin Nov 4, 2012 · The ALLHAT study, sponsored by the US National Heart, Lung, and Blood Institute, was intended to evaluate whether the occurrence of fatal coronary heart disease (CHD) or nonfatal myocardial infarction was lower for high-risk hypertensive patients aged 55 years or older treated with doxazosin, amlodipine, or lisinopril, in comparison with Jan 31, 2007 · In ALLHAT, the doxazosin arm was discontinued early because of an increased rate of combined cardiovascular disease, stroke, and heart failure. We applied trajectory-based modeling to data on 39 763 study participants of the ALLHAT (Antihypertensive and Lipid-Lowering Nov 1, 2001 · The data from the ALLHAT study indicate that the risk of CHF with doxazosin was more than 100% (relative risk 2. 2000 Mar 30;142(13):4-5. The doxazosin arm was terminated early, when the trial’s safety and monitoring board noted a twofold higher incidence of May 5, 2009 · The ALLHAT investigators acknowledge contributions of study medications supplied by Pfizer, Inc. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study J Clin Hypertens (Greenwich) . analyses. 10-12 Although ALLHAT answered questions about the compar-ative effectiveness of antihypertensive treatments for HF Mar 1, 2003 · The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) compared four antihypertensive agents in patients 55 years and older: chlorthalidone, doxazosin, amlodipine, and lisinopril. Nov 1, 2001 · The data from the ALLHAT study indicate that the risk of CHF with doxazosin was more than 100% (relative risk 2. Evolving ECG LVH and BP lowering served as mediators. The trial was Sep 1, 2002 · We are following with great interest the discussion in the American Journal of Hypertension about the use of doxazosin in hypertension, as reflected by the correspondence between Drs. ” Their concerns are probably held by many who were surprised or even disappointed by the ALLHAT publication. Several news agencies published reports of the study, and comments appeared in a few medical journals. chlorthalidone: The antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). It was randomized and blinded and compared several different modalities of treatment in more than 40,000 people. 36 It should not be taken as just another study comparing different drugs; the results should be reviewed carefully and incorporated into the management of all patients with hypertension. 11 The purpose of this paper Jan 31, 2007 · The ALLHAT investigators acknowledge contributions of study medications supplied by Pfizer, Inc (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol‐Myers Squibb (pravastatin), and financial support provided by Pfizer, Inc, Dr. 3 This despite the protocol limitations on proper drug combination, on which I will comment later. • ALLHAT STUDY RESULTS: DOXAZOSIN STUDY STOPPED As in all major clinical trials, an advisory committee periodically reviews the safety of the ALLHAT. Under the auspices Jun 17, 2020 · The ALLHAT study was supported by the National Heart, Lung, and Blood Institute (NO1-HC-35130). The purpose of our study was to compare the effect of doxazosin, in different doses, to ACE inhibitor Jul 1, 2003 · In early 2000, the doxazosin arm of ALLHAT was stopped because of a significantly higher incidence of cardiovascular events in the group assigned to the α-blocker doxazosin versus the chlorthalidone group. Chlorthalidone was at least equivalent to amlodipine and lisinopril in all of the outcomes Cardiovascular outcomes using doxazosin vs. The ALLHAT investigators received contributions of study medications supplied by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol Myers Squibb (pravastatin); and financial support provided by Pfizer. The author Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial Grade 1 hypertension. The primary outcome (i. Apr 14, 2003 · Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) compared four antihypertensive agents in patients 55 years and older: chlorthalidone, doxazosin, amlodipine, and lisinopril. Aug 18, 2003 · The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an α-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and Doxazosin and chlorthalidone arm of study stopped early In February 2000 the doxazosin (Cardoxan, Carduran and Dosan) arm of the ALLHAT trial was stopped early. The doxazosin arm was terminated early because of an excess of congestive heart failur … expectations, the ALLHAT showed that chlorthalidone was superior to amlodipine, lisinopril, and doxazosin in preventing HF. The Validation Study provided conclusive evidence that ALLHAT findings of chlorthalidone‐based treatment’s superiority over amlodipine‐, lisinopril‐, and doxazosin‐based strategies in preventing the transition from hypertension to symptomatic HF were not due to misdiagnosis of HF by ALLHAT site physicians. JAMA 2000 Objective To compare the effect of doxazosin, an α-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril. 32) higher than the risk in patients who were treated with chlorthalidone . The doxazosin arm was terminated early because of an excess of congestive heart failure. e. ALLHAT was not Elliott WJ: ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Although systolic blood pressure was 2 to 3 mm Hg higher in the doxazosin group than in the diuretic group (diastolic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) investigators acknowledge study medications contributed by Pfizer Inc (amlodipine besylate and doxazosin mesylate), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin sodium) and financial support provided by Pfizer Inc. 13 In the diabetic subgroup, the rates of CVD and coronary HF were significantly higher in participants randomized to doxazosin versus May 30, 2017 · Randomized trials of hypertension have seldom examined heterogeneity in response to treatments over time and the implications for cardiovascular outcomes. 16 ALLHAT clearly demonstrated that mono‐therapy with doxazosin as initial therapy was not as effective as traditional therapy with chlorthalidone. ALLHAT is a randomised, double blind, active controlled trial in the USA and Canada, which began in February 1994. May 25, 2007 · This study was supported by contract NO1‐HC‐35130 from the National Heart, Lung, and Blood Institute. Results A consort diagram (Figure 1) shows the number of partici-pants who entered the trial and their status at the end of the in-trial period (March, 2002) by sex. Dec 18, 2002 · ALLHAT provided a diverse population base for ALLHAT-LLT. Oct 1, 2003 · Major cardiovascular events in hypertensive patients randomized to doxazosin vs. The data were validated after a rigorous evaluation of all hospitalized HF events ( 17 ). The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) just published,1 is the largest clinical trial so far conducted. Unless the drug regimen had to be tapered for safety reasons, individuals continued any prior antihypertensive medications until they received randomized study drug, at which point they stopped taking all previous medications. Apr 29, 2000 · In his March 1·1 Commentary,1 Franz Messerli informs us that the data safety monitoring board advised stopping of the doxazosin treatment arm of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) trial. Incident symptomatic HF was the primary outcome. Dec 18, 2002 · Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Nov 1, 2001 · The results of ALLHAT regarding doxazosin were first made public by a presentation at the meeting of the American College of Cardiology, March 2000, and the subsequent publication. Nov 1, 2001 · Drs. Krakoff and Alderman regarding the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). EVENTS IN HYPERTENSIVE PATIENTS RANDOMIZED TO DOXAZOSIN VS CHLORTHALIDONE. 1 In 1997 to 1998 we conducted a relatively large local study Apr 1, 2007 · The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the ALLHAT was not a placebo-controlled trial, but rather an active-controlled one, thus the study did not permit an assessment of whether doxazosin is better than placebo. Although systolic blood pressure was 2 to 3 mm Hg higher in the doxazosin group than in the diuretic group (diastolic May 21, 2007 · The ALLHAT study is a landmark trial confirming previous data and clarifying some of the myths and misconceptions that have been promulgated through the years. Am J Hypertens 1996, 9 :409–411. 04; 95% confidence interval 1. ALLHAT investigators received contributions of study medications supplied by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol‐Myers Squibb (pravastatin) and financial support provided by Pfizer. 20 , 21 There was considerable rationale for the inclusion of a peripheral α‐adrenergic Study Overview. 8,9 The subsequent ALLHAT HF validation study reinforced the original ALLHAT results. death from coronary heart disease, nonfatal myocardial infarction, stroke, coronary revascularisation, hospitalised or treated angina, treated or hospitalised congestive heart failure, and peripheral . Ann Intern Med 137: 313–320. Further details are provided in the major ALLHAT out-comes article,10 the ALLHAT extension article,18 and the ALLHAT extension protocol (www. [1] The data regarding heart failure is more contentious and has been a controversial end point in ALLHAT ever since the premature discontinuation of the doxazosin arm of the study for a reported excess of heart failure when compared to the diuretic. Background: ALLHAT, a randomized, double-blind, active-controlled hypertension treatment trial in 42,418 patients, reported that a thiazide-type diuretic (chlorthalidone) was superior to a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha1-blocker (doxazosin) in preventing the new onset of heart failure (HF). Mar 30, 2000 · [ALLHAT Study: doxazosin arm is discontinued. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial . There were 17719 men Apr 22, 2011 · In the ALLHAT study, chlorthalidone was superior to doxazosin, lisinopril, and amlodipine in preventing HF (4,5). allhat. ALLHAT investigators received contributions of study medications supplied by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), Bristol-Myers Squibb (pravastatin), and financial support provided by Pfizer. The number of participants in the three arms of the ALLHAT study (n = 33 357) is only slightly less than in the trials comparing new and old drug classes in the BPLTTC overview (n = 37 402). Alpha blocker is less effective than a diuretic] MMW Fortschr Med. The effect of doxazosin in the treatment of drug‐resistant hypertension Nov 8, 2010 · Although the ALLHAT study found the α-blocker doxazosin to be inferior to other antihypertensive agents as first-step treatment of hypertension, 49 and has discouraged research and clinical interest in α-blockers, considerable evidence supports greater use of the α-blocker doxazosin in combination with a β-blocker in treating patients with Nov 1, 2001 · The report comparing doxazosin with chlorthalidone in ALLHAT discusses possible explanations for the findings. This study, comparing pravastatin with usual care, assessed the value of cholesterol lowering in a population underrepresented in prior cholesterol trials—individuals with well-controlled hypertension, almost half women, 38% black, 35% with a history of diabetes, 55% at least 65 years Nov 1, 2001 · This commentary has two purposes: to summarize the rationale, design and initial results of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial; and to provide a history of the response to ALLHAT that led to a civil action and a Citizens Petition that was the basis for a public hearing by the US Food and Drug Administration, in May 2001. Poulter and Williams and Drs. percentage of patients on doxazosin developed congestive heart failure (which was a secondary endpoint) and that it seemed unlikely that doxazosin would confer more benefits with regard to the primary endpoint (coronary heart disease) than chlorthalidone. combined fatal CHD and non-fatal myocardial infarction) was not significantly different between amlodipine and chlorthalidone in May 10, 2007 · DR MOSER: ALLHAT (the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial) was a landmark study, the largest hypertension study to date. 79–2. 2, 7 This again may have much to do with trial design. 3 years. lvgy xevaq clnpz ushqx cgnkmt pfvvlk awzuu tycepr oknl ryjqqs